Main clinical characteristics according to cytogenetic subgroups
| Cytogenetic subgroup . | Patients, N (%) . | Males, N (%) . | Median age, y (range) . | Age 15-24 y, N (%) . | Age 25-44 y, N (%) . | Age 45-59 y, N (%) . | Median WBC 109/L (range) . | WBC >30 × 109/L, N (%) . | CNS+, N (%) . | CD10-negative, N (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 542 | 302 (56) | 38 (15-59) | 151 (28) | 206 (38) | 185 (34) | 8.21 (0.4-474) | 142 (26) | 24 (4) | 165 (32) |
| Primary subgroups† | ||||||||||
| t(4;11)(q21;q23) | 72 (13) | 34 (47) | 41 (18-59) | 15 | 36 | 21 | 113.3 (3.8-474)** | 55 (76)** | 1 | 62 (96)** |
| Other t(v;11q23) | 11 (2) | 7 (64) | 31 (21-53) | 3 | 5 | 3 | 32.9 (1.6-142)** | 7 (64)** | 2 | 9 (82)** |
| t(1;19)(q23;p13) | 28 (5) | 11 (39) | 36 (18-59) | 7 | 14 | 7 | 13 (2.6-396)* | 5 (18) | 4 | 0 (0)** |
| Ho-Tr | 33 (6) | 18 (55) | 53 (22-59)** | 1 | 4 | 28 (85)** | 6.4 (0.8-134) | 1 (3) | 0 | 17 (55)** |
| HeH | 36 (7) | 25 (69) | 30 (17-59) | 15 | 10 | 11 | 2.8 (0.7-62)** | 1 (3)* | 1 | 5 (14) |
| ETV6-RUNX1 | 2 (0.4) | 2 | 20 (19-20) | 2 | 0 | 0 | 8.5 (6.9-10) | 0 (0) | 0 | 0 (0) |
| iAMP21 | 3 (0.5) | 3 | 20 (18-20)* | 3 | 0 | 0 | 3.7 (1.7-25) | 0 (0) | 0 | 0 (0) |
| 14q32/IGH | 27 (5) | 16 (59) | 43 (18-59) | 5 | 11 | 11 | 7.5 (1.3-262) | 4 (15) | 2 | 3 (12) |
| Other abnormalities | 210 (39) | 119 (57) | 34 (15-59) | 63 | 79 | 68 | 6.9 (0.4-343) | 50 (24) | 9 | 40 (20) |
| No identified abnormalities | 120 (22) | 68 (57) | 37 (16-59) | 37 | 47 | 36 | 5.6 (0.5-342) | 19 (16) | 5 | 29 (25) |
| Secondary abnormalities‡ | ||||||||||
| del(6q) | 23/492 (5) | 12 (52) | 40 (18-58) | 5 | 9 | 9 | 12.9 (1.5-396) | 9 (39) | 3 | 5 (22) |
| del(7p) | 29/494 (6) | 19 (66) | 42 (18-59) | 6 | 11 | 12 | 8.7 (1.2-438) | 10 (34) | 1 | 6 (22) |
| Monosomy 7 | 53/510 (10) | 30 (60) | 49 (18-59)** | 7 | 11 | 35 (66)** | 5.2 (0.7-45)** | 2 (4)** | 0 | 19 (38) |
| del(9p) | 67/493 (14) | 37 (55) | 35 (18-59) | 22 | 21 | 24 | 7.9 (0.7-396) | 16 (24) | 5 | 6 (9)** |
| Monosomy 9 | 39/511 (8) | 22 (56) | 53 (18-59)** | 4 | 7 | 28 (74)** | 8.2 (0.9-222) | 4 (10)* | 0 | 17 (46) |
| del(13q) | 15/494 (3) | 10 (66) | 42 (19-58) | 4 | 5 | 6 | 7.3 (1-159) | 3 (20) | 2 | 2 (13) |
| Monosomy 13 | 32/506 (6) | 16 (50) | 51 (19-59)** | 3 | 5 | 24 (75)** | 6.7 (0.7-142)* | 2 (6)** | 0 | 13 (43) |
| del(17p) | 11/493 (2) | 6 (55) | 33 (19-49) | 3 | 4 | 4 | 6.6 (1.2-124) | 3 (27) | 0 | 4 (40) |
| Monosomy 17 | 36/508 (7) | 21 (58) | 53 (19-59)** | 2 | 5 | 29 (81)** | 6.5 (0.8-57)** | 1 (3)** | 0 | 13 (68) |
| Complex karyotype | 27/527 (5) | 19 (70) | 33 (18-59) | 10 | 9 | 8 | 6.6 (1.1-222) | 2 (7)* | 0 | 5 (19) |
| Monosomal karyotype | 82/518 (16) | 47 (57) | 48 (18-59)** | 15 | 17 | 50 (61)** | 6.7 (0.7-230)** | 8 (10)** | 0* | 27 (35) |
| Cytogenetic subgroup . | Patients, N (%) . | Males, N (%) . | Median age, y (range) . | Age 15-24 y, N (%) . | Age 25-44 y, N (%) . | Age 45-59 y, N (%) . | Median WBC 109/L (range) . | WBC >30 × 109/L, N (%) . | CNS+, N (%) . | CD10-negative, N (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 542 | 302 (56) | 38 (15-59) | 151 (28) | 206 (38) | 185 (34) | 8.21 (0.4-474) | 142 (26) | 24 (4) | 165 (32) |
| Primary subgroups† | ||||||||||
| t(4;11)(q21;q23) | 72 (13) | 34 (47) | 41 (18-59) | 15 | 36 | 21 | 113.3 (3.8-474)** | 55 (76)** | 1 | 62 (96)** |
| Other t(v;11q23) | 11 (2) | 7 (64) | 31 (21-53) | 3 | 5 | 3 | 32.9 (1.6-142)** | 7 (64)** | 2 | 9 (82)** |
| t(1;19)(q23;p13) | 28 (5) | 11 (39) | 36 (18-59) | 7 | 14 | 7 | 13 (2.6-396)* | 5 (18) | 4 | 0 (0)** |
| Ho-Tr | 33 (6) | 18 (55) | 53 (22-59)** | 1 | 4 | 28 (85)** | 6.4 (0.8-134) | 1 (3) | 0 | 17 (55)** |
| HeH | 36 (7) | 25 (69) | 30 (17-59) | 15 | 10 | 11 | 2.8 (0.7-62)** | 1 (3)* | 1 | 5 (14) |
| ETV6-RUNX1 | 2 (0.4) | 2 | 20 (19-20) | 2 | 0 | 0 | 8.5 (6.9-10) | 0 (0) | 0 | 0 (0) |
| iAMP21 | 3 (0.5) | 3 | 20 (18-20)* | 3 | 0 | 0 | 3.7 (1.7-25) | 0 (0) | 0 | 0 (0) |
| 14q32/IGH | 27 (5) | 16 (59) | 43 (18-59) | 5 | 11 | 11 | 7.5 (1.3-262) | 4 (15) | 2 | 3 (12) |
| Other abnormalities | 210 (39) | 119 (57) | 34 (15-59) | 63 | 79 | 68 | 6.9 (0.4-343) | 50 (24) | 9 | 40 (20) |
| No identified abnormalities | 120 (22) | 68 (57) | 37 (16-59) | 37 | 47 | 36 | 5.6 (0.5-342) | 19 (16) | 5 | 29 (25) |
| Secondary abnormalities‡ | ||||||||||
| del(6q) | 23/492 (5) | 12 (52) | 40 (18-58) | 5 | 9 | 9 | 12.9 (1.5-396) | 9 (39) | 3 | 5 (22) |
| del(7p) | 29/494 (6) | 19 (66) | 42 (18-59) | 6 | 11 | 12 | 8.7 (1.2-438) | 10 (34) | 1 | 6 (22) |
| Monosomy 7 | 53/510 (10) | 30 (60) | 49 (18-59)** | 7 | 11 | 35 (66)** | 5.2 (0.7-45)** | 2 (4)** | 0 | 19 (38) |
| del(9p) | 67/493 (14) | 37 (55) | 35 (18-59) | 22 | 21 | 24 | 7.9 (0.7-396) | 16 (24) | 5 | 6 (9)** |
| Monosomy 9 | 39/511 (8) | 22 (56) | 53 (18-59)** | 4 | 7 | 28 (74)** | 8.2 (0.9-222) | 4 (10)* | 0 | 17 (46) |
| del(13q) | 15/494 (3) | 10 (66) | 42 (19-58) | 4 | 5 | 6 | 7.3 (1-159) | 3 (20) | 2 | 2 (13) |
| Monosomy 13 | 32/506 (6) | 16 (50) | 51 (19-59)** | 3 | 5 | 24 (75)** | 6.7 (0.7-142)* | 2 (6)** | 0 | 13 (43) |
| del(17p) | 11/493 (2) | 6 (55) | 33 (19-49) | 3 | 4 | 4 | 6.6 (1.2-124) | 3 (27) | 0 | 4 (40) |
| Monosomy 17 | 36/508 (7) | 21 (58) | 53 (19-59)** | 2 | 5 | 29 (81)** | 6.5 (0.8-57)** | 1 (3)** | 0 | 13 (68) |
| Complex karyotype | 27/527 (5) | 19 (70) | 33 (18-59) | 10 | 9 | 8 | 6.6 (1.1-222) | 2 (7)* | 0 | 5 (19) |
| Monosomal karyotype | 82/518 (16) | 47 (57) | 48 (18-59)** | 15 | 17 | 50 (61)** | 6.7 (0.7-230)** | 8 (10)** | 0* | 27 (35) |